Abstract
There has been significant progress in defining the risks associated with the use of nonsteroidal anti-inflammatory drugs. There is now clear consensus that certain patient subsets are at an increased risk for gastroduodenal mucosal damage when those patients are treated with these drugs. The therapy for treating mucosal damage or preventing it has also been better defined. The studies published this year have provided a better understanding of those patients who should be considered as candidates for possible therapy for prophylaxis against mucosal damage and which drugs might be useful. The patients who are at risk to develop renal dysfunction remain less well defined. This paper reviews the current relevant literature.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
